GCM
CHRS icon

Graham Capital Management’s Coherus Oncology CHRS Stock Holding History

Graham Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-231,255
Closed -$169K – 1290
2025
Q2 		$169K Buy
231,255
+73,280
+46% +$63.3K ﹤0.01% 1153
2025
Q1 		$127K Buy
157,975
+81,675
+107% +$94K ﹤0.01% 1188
2024
Q4 		$105K Buy
76,300
+7,649
+11% +$8.58K ﹤0.01% 1150
2024
Q3 		$71.4K Buy
68,651
+33,170
+93% +$45.5K ﹤0.01% 1028
2024
Q2 		$61.4K Buy
+35,481
New +$71.4K ﹤0.01% 977
2023
Q4 		– Sell
-131,184
Closed -$491K – 1038
2023
Q3 		$491K Buy
131,184
+2,645
+2% +$12.2K 0.01% 570
2023
Q2 		$549K Buy
+128,539
New +$758K 0.02% 532
2022
Q4 		– Sell
-278,770
Closed -$2.68M – 1078
2022
Q3 		$2.68M Buy
278,770
+83,349
+43% +$843K 0.11% 148
2022
Q2 		$1.41M Buy
195,421
+168,105
+615% +$1.46M 0.06% 316
2022
Q1 		$352K Buy
+27,316
New +$347K 0.01% 679

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Graham Capital Management's CHRS Position: Q3 2025 in Review

Graham Capital Management sold out of Coherus Oncology (CHRS) in Q3 2025, closing a stake of 231,255 shares — an estimated $169K sold.

Graham Capital Management first reported a position in CHRS in Q1 2022 and held it in 10 quarters. The position peaked at $2.68M in Q3 2022. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Graham Capital Management reported no remaining Coherus Oncology position as of Q3 2025 after selling out during the quarter.
  • Graham Capital Management sold 231,255 Coherus Oncology shares in Q3 2025, an estimated $169K.
  • Graham Capital Management first reported a position in Coherus Oncology in Q1 2022 and held it in 10 quarters.
  • Graham Capital Management's Coherus Oncology position peaked at $2.68M in Q3 2022.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.